Upholding of WARF stem cell patent reversed
By The Business Journal of Milwaukee,
The Business Journal of Milwaukee
| 05. 03. 2010
The U.S. Patent and Trademark Office's Board of Appeals and Interference has reversed an earlier decision from the Patent Office's re-examination division that upheld the claims of one of the stem cell lines held by the Wisconsin Alumni Research Foundation.
The patent covers one of the three key stem cell lines that were challenged through re-examination proceedings initiated in October 2006 at the request of consumer watchdog groups New York City-based Public Patent Foundation and the Santa Monica, Calif.-based Foundation for Taxpayer and Consumer Rights, now called Consumer Watchdog.
The re-examination division upheld the validity of the patents in mid-2008, and the groups were allowed to challenge one of the patents in an appeal to the Board of Appeals and Interference.
The groups argue that the work done by University of Wisconsin researcher James Thomson to isolate stem cell lines was obvious in the light of previous scientific research, making his work unpatentable. The groups claimed the three WARF patents were "impeding scientific progress and driving vital stem cell research overseas."
The patent office rejected the arguments by the groups...
Related Articles
By Gemma Conroy, Nature | 06.27.2024
Image by Robina Weermeijer from Unsplash
A molecular-editing tool that’s small enough to be delivered to the brain shuts down the production of proteins that cause prion diseases, a rare but deadly group of neurodegenerative disorders.
The system — known...
By Julia Black and Margaux MacColl, The Information [cites CGS' Katie Hasson] | 07.19.2024
When venture capitalist Jack Abraham first began dating his wife, Gabriella Massamillo, he insisted on one condition: that when they were ready to have children, she’d be willing to conceive using in vitro fertilization. Abraham had lost both his mother...
By Kevin Davies, Genetic Engineering & Biotechnology News | 06.27.2024
Physician-scientist Matthew Porteus, MD, PhD, has been a mainstay in the genome editing field for more than two decades. He trained at Stanford University Medical School before completing his residency and hematology/oncology fellowship at Boston Children’s Hospital/Dana Farber Cancer Institute...
By Robert F. Service, Science | 07.04.2024
Image by Ed Uthman from Flickr
Last year, the U.S. Food and Drug Administration (FDA) approved two gene therapy procedures that can treat and, in some cases essentially cure sickle cell disease, a genetic blood disorder that causes pain and...